| Market Cap | 10.01M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -8.28M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -31.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -61.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -91.00% |
| Recommedations | 2.00 | Quick Ratio | 2.87 | Shares Outstanding | 2.93M | 52W Low Chg | 2.00% |
| Insider Own | 0.35% | ROA | -82.53% | Shares Float | 2.65M | Beta | - |
| Inst Own | 9.79% | ROE | -189.06% | Shares Shorted/Prior | 143.66K/2.76K | Price | 3.43 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 13,779 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 12 | Volume | 989 | Change | -2.56% |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.